{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:27:29Z","timestamp":1788276449928,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psilocybin treatment has shown promise for treatment-resistant obsessive-compulsive disorder (OCD), yet clinical response is variable. Little is known about the subjective experiences associated with divergent outcomes or the psychological processes differentiating responders from non-responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A qualitative case comparison was conducted using semi-structured interviews from six participants enrolled in a randomized controlled trial of single-dose psilocybin with psychological support for treatment-resistant OCD. Participants were purposively selected to contrast three responders with marked symptom improvement and three non-responders with minimal improvement or worsening symptoms. Interviews were conducted approximately 1-2 months post-dosing and analyzed using reflexive thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four dialectical themes captured key contrasts between responders and non-responders: 1) Surrender vs. Control, 2) Disidentification with OCD and Self-Compassion vs. Overidentification with OCD, 3) Emotional Breakthrough vs. Emotional Containment, and 4) Reappraisal of OCD as Inconsequential vs. Sustained Conviction in OCD. Among responders, surrender during the acute session appeared to enable subsequent psychological shifts. The self was separated from OCD while self-compassion was developed; emotions were experienced directly in the body without the usual cognitive filtering; and OCD-related concerns were spontaneously reappraised as arbitrary and inconsequential. Among non-responders, control was maintained or surrender was experienced as overwhelming; identification with OCD and persistent self-criticism remained; difficult emotions were avoided or accessed without lasting breakthrough; and conviction in OCD\u2019s logic and demands was maintained or intensified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The distinction between intellectual insight and embodied change emerged as central: responders described viscerally felt insights that spontaneously shaped behavior, whereas non-responders articulated understanding without corresponding change in feeling or action. Across themes, surrender during the acute session appeared to enable subsequent shifts in self-concept, emotional processing, and reappraisal of OCD as inconsequential. Therapeutic benefit may depend on the quality of psychological engagement\u2014particularly the capacity to surrender, tolerate intense emotion, and translate insight into behavioral change\u2014rather than experiential intensity alone. The distinction between intellectual insight and embodied change emerged as central to understanding differential response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1791689","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:09:02Z","timestamp":1788275342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD"],"prefix":"10.3389","volume":"17","author":[{"given":"Gabrielle","family":"Agin-Liebes","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shnayder","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geena","family":"Fram","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Cody","family":"Swift","sequence":"additional","affiliation":[{"name":"RiverStyx Foundation","place":["Santa Cruz, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Ching","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Jankovsky","sequence":"additional","affiliation":[{"name":"Eastern Michigan University","place":["Ypsilanti, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Hokanson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pittenger","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Department of Psychology, Yale University","place":["New Haven, CT, United States"]},{"name":"Center for Brain and Mind Health, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Yale Child Study Center, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Department of Neuroscience, Yale University School of Medicine","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kelmendi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1402176","article-title":"Obsessive\u2013compulsive disorder","volume":"371","author":"Grant","year":"2014","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300951","article-title":"Influence of study characteristics, methodological rigour and publication bias on efficacy of pharmacotherapy in obsessive-compulsive disorder: a systematic review and meta-analysis of randomised, placebo-controlled trials","volume":"27","author":"Cohen","year":"2024","journal-title":"BMJ Ment Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2025.152619","article-title":"Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: a pharmacological challenge study","volume":"142","author":"Pellegrini","year":"2025","journal-title":"Compr Psychiatry"},{"key":"B9","unstructured":"Psilocybin for treatment-resistant OCD: a randomized controlled trial\n          \n          \n            \n              Kelmendi\n              B\n            \n            \n              Adams\n              T\n            \n            \n              Ching\n              THW\n            \n            \n              Grazioplene\n              R\n            \n            \n              Kichuk\n              S\n            \n            \n              Fram\n              G\n            \n          \n          Psyarxiv\n          \n          2026"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/02698811261424214","article-title":"A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive\u2013compulsive disorder","volume":"40","author":"Moreno","year":"2026","journal-title":"J Psychopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1726818","article-title":"Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis","volume":"16","author":"Ching","year":"2025","journal-title":"Front Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1037\/adb0000935","article-title":"Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis","volume":"38","author":"Agin-Liebes","year":"2024","journal-title":"Psychol Addict Behav"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/00221678211022949","article-title":"Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: an interpretive phenomenological analysis","volume":"64","author":"Agin-Liebes","year":"2021","journal-title":"J Humanistic Psychol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J Humanistic Psychol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118780612","article-title":"Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts","volume":"32","author":"Noorani","year":"2018","journal-title":"J Psychopharmacol"},{"key":"B16","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/2159676X.2019.1628806","article-title":"Reflecting on reflexive thematic analysis","volume":"11","author":"Braun","year":"2019","journal-title":"Qual Res Sport Exercise Health"},{"key":"B19","volume-title":"Abductive Analysis: Theorizing Qualitative Research","author":"Tavory","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/0022167817706884","article-title":"Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis","volume":"57","author":"Belser","year":"2017","journal-title":"J Humanistic Psychol"},{"key":"B21","unstructured":"Dedoose: Web-Based Qualitative and Mixed Methods Research Software\n          \n          2024"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00005","article-title":"Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance","volume":"11","author":"Wolff","year":"2020","journal-title":"Front Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J Psychopharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jclp.20080","article-title":"Understanding and treating incompleteness in obsessive\u2010compulsive disorder","volume":"60","author":"Summerfeldt","year":"2004","journal-title":"J Clin Psychol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.janxdis.2016.02.007","article-title":"Into the unknown: a review and synthesis of contemporary models involving uncertainty","volume":"39","author":"Carleton","year":"2016","journal-title":"J Anxiety Disord"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6185(02)00182-2","article-title":"Intolerance of uncertainty in obsessive-compulsive disorder","volume":"17","author":"Tolin","year":"2003","journal-title":"J Anxiety Disord"},{"key":"B27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0005-7967(02)00044-X","article-title":"\u201cNot just right experiences\u201d: perfectionism, obsessive\u2013compulsive features and general psychopathology","volume":"41","author":"Coles","year":"2003","journal-title":"Behav Res Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(94)90132-5","article-title":"Obsessions, overvalued ideas, and delusions in obsessive-compulsive disorder","volume":"32","author":"Kozak","year":"1994","journal-title":"Behav Res Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7967(00)00053-X","article-title":"Predictive validity of the overvalued ideas scale: outcome in obsessive\u2013compulsive and body dysmorphic disorders","volume":"39","author":"Neziroglu","year":"2001","journal-title":"Behav Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.12.007","article-title":"Obsessive\u2013compulsive disorder with poor insight: a three-year prospective study","volume":"34","author":"Catapano","year":"2010","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/02698811221080165","article-title":"Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca","volume":"36","author":"Agin-Liebes","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brat.2014.04.006","article-title":"Maximizing exposure therapy: an inhibitory learning approach","volume":"58","author":"Craske","year":"2014","journal-title":"Behav Res Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brat.2018.06.005","article-title":"Adding acceptance and commitment therapy to exposure and response prevention for obsessive-compulsive disorder: a randomized controlled trial","volume":"108","author":"Twohig","year":"2018","journal-title":"Behav Res Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcbs.2019.11.002","article-title":"Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame","volume":"15","author":"Sloshower","year":"2020","journal-title":"J Contextual Behav Sci"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1791689\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:09:04Z","timestamp":1788275344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1791689\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":34,"alternative-id":["10.3389\/fpsyt.2026.1791689"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1791689","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1791689"}}